Abstracts tagged "outcome measures and systemic lupus erythematosus (SLE)"

Abstract Number: 264 • 2018 ACR/ARHP Annual Meeting
Relationships between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus
Kimberly DeQuattro¹, Laura Trupin¹, Jing Li¹, Patricia Katz², Cristina Lanata¹, Edward H. Yelin³, Stephanie Rush³, Lindsey A. Criswell², Louise Murphy⁴, Maria Dall'Era⁵ and Jinoos Yazdany¹, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA, ⁵University of California, San Francisco, San Francisco, CA
Background/Purpose: Adverse childhood experiences (ACEs) such as abuse, neglect and domestic violence are associated with poor adult health status and immune dysregulation. The extent and…
Abstract Number: 1668 • 2018 ACR/ARHP Annual Meeting
Construction and Validation of a Frailty Index As a Novel Health Measure in Systemic Lupus Erythematosus
Alexandra Legge¹, Susan Kirkland², Kenneth Rockwood³, Pantelis Andreou², Sang-Cheol Bae⁴, Caroline Gordon⁵, Juanita Romero-Díaz⁶, Jorge Sanchez-Guerrero⁷, Daniel J. Wallace⁸, Sasha Bernatsky⁹, Ann E. Clarke¹⁰, Joan T. Merrill¹¹, Ellen M. Ginzler¹², Paul R. Fortin¹³, Dafna D Gladman¹⁴, Murray Urowitz⁷, Ian N. Bruce¹⁵, David A. Isenberg¹⁶, Anisur Rahman¹⁷, Graciela S. Alarcón¹⁸, Michelle Petri¹⁹, Munther A Khamashta²⁰, Mary Dooley²¹, Rosalind Ramsey-Goldman²², Susan Manzi²³, Kristján Steinsson²⁴, Asad A Zoma²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat Inanc²⁹, Ronald F van Vollenhoven³⁰, Andreas Jönsen³¹, Ola Nived³¹, Manuel Ramos-Casals³², Diane L. Kamen³³, Kenneth C. Kalunian³⁴, Søren Jacobsen³⁵, Christine A. Peschken³⁶, Anca Askanase³⁷ and John G. Hanly³⁸, ¹Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ²Department of Community Health & Epidemiology, Dalhousie University, Halifax, NS, Canada, ³Department of Medicine, Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada, ⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁵Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁷University of Toronto Lupus Research Program, Toronto Western Hospital, Toronto, ON, Canada, ⁸Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Divisions of Rheumatology and Clinical Epidemiology, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹²Rheumatology, SUNY Downstate Medical Center, Brooklyn, NY, ¹³Medicine, CHU de Québec - University of Laval, Quebec, QC, Canada, ¹⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁵Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ¹⁶University College London, London, United Kingdom, ¹⁷Rayne Institute, University College London, London, United Kingdom, ¹⁸University of Alabama at Birmingham, Birmingham, AL, ¹⁹Johns Hopkins University School of Medicine, Baltimore, MD, ²⁰Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, ²¹Dooley Rheumatology, Chapel Hill Doctors, Chapel Hill, NC, ²²FSM, Northwestern University, Chicago, IL, ²³Autoimmunity Institute and Medicine Institute, Allegheny Health Network, Pittsburgh, PA, ²⁴Rheumatology, Univ. Hospital, Reykjavik, Iceland, ²⁵Lanarkshire Center for Rheumatology, Hairmyres Hospital, East Kilbride, East Kilbride, Scotland, United Kingdom, ²⁶The Feinstein Institute for Medical Research, Manhasset, NY, ²⁷Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ²⁸Emory University School of Medicine, Atlanta, GA, ²⁹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³⁰Unit for clinical therapy research (ClinTRID), Karolinska Institute, Stockholm, Sweden, ³¹Rheumatology, Lund University, Department of Clinical Sciences, Lund, Sweden, ³²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ³³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ³⁴Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ³⁵Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³⁶RR 149G, University of Manitoba, Winnipeg, MB, Canada, ³⁷Rheumatology, Columbia University, College of Physician and Surgeons, New York, NY, ³⁸Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
Background/Purpose: Clinical outcomes in SLE are challenging to predict. In non-SLE populations, susceptibility to adverse outcomes has been measured using a frailty index (FI), which…
Abstract Number: 1711 • 2018 ACR/ARHP Annual Meeting
Utility of the Lupus Low Disease Activity State (LLDAS) in Discriminating Responders in the BLISS-52 and BLISS-76 Phase 3 Trials of Intravenous Belimumab in Systemic Lupus Erythematosus
Shereen Oon¹, Molla Huq², Vera Golder³, Emily Ong⁴, Eric Morand⁵ and Mandana Nikpour⁶, ¹The University of Melbourne at St Vincent's Hospital, Fitzroy, Australia, ²The University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ³School of Clinical Sciences at Monash Health, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁴School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁵Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ⁶The University of Melbourne, Melbourne, Australia, Melbourne, Australia
Background/Purpose: Measurement of treatment response in SLE clinical trials has been based on measurement of change from baseline; however a treat-to-target analysis has seldom been…
Abstract Number: 2786 • 2018 ACR/ARHP Annual Meeting
Prospective Multicenter Validation Study of the Lupus Low Disease Activity State – a Treatment Target for Systemic Lupus Erythematosus
Vera Golder¹, Rangi Kandane-Rathnayake², Molla Huq³, Worawit Louthrenoo⁴, Shue-Fen Luo⁵, Yeong-Jian Wu⁶, Aisha Lateef⁷, Sargunan Sockalingam⁸, Susan Morton⁹, Sandra V. Navarra¹⁰, Leonid Zamora¹¹, Laniyati Hamijoyo¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹⁴, Madelynn Chan¹⁵, Sean O'Neill¹⁶, Fiona Goldblatt¹⁷, Chak Sing Lau¹⁸, Zhan-Guo Li¹⁹, Alberta Y. Hoi², Mandana Nikpour²⁰ and Eric Morand²¹, ¹School of Clinical Sciences at Monash Health, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ³The University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁴Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁵Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁶Chang Gung University, Taoyuan County, Taiwan, ⁷Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, ⁸University of Malaya, Kuala Lumpur, Malaysia, ⁹Monash Health, Melbourne, Australia, ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹²University of Padjadjaran, Bandung, Indonesia, ¹³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁴Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶University of New South Wales, Sydney, Australia, ¹⁷Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ¹⁸Medicine, The University of Hong Kong, Hong Kong, Hong Kong, ¹⁹Department of Rheumatology and Immunology, People’s Hospital, Peking University Health Science Center,, Beijing, China, ²⁰The University of Melbourne, Melbourne, Australia, Melbourne, Australia, ²¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: The adoption of treat to target approaches for Systemic Lupus Erythematosus (SLE) requires the definition of a target state validated for improved patient outcomes.…
Abstract Number: 2930 • 2018 ACR/ARHP Annual Meeting
Prospective Comparison of Remission and Lupus Low Disease Activity State – Effect on Disease Outcomes in Systemic Lupus Erythematosus
Vera Golder¹, Rangi Kandane-Rathnayake², Molla Huq³, Worawit Louthrenoo⁴, Shue-Fen Luo⁵, Yeong-Jian Wu⁶, Aisha Lateef⁷, Sargunan Sockalingam⁸, Susan Morton⁹, Sandra V. Navarra¹⁰, Leonid Zamora¹¹, Laniyati Hamijoyo¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹⁴, Madelynn Chan¹⁵, Sean O'Neill¹⁶, Fiona Goldblatt¹⁷, Chak Sing Lau¹⁸, Zhan-Guo Li¹⁹, Alberta Y. Hoi², Mandana Nikpour²⁰ and Eric Morand²¹, ¹School of Clinical Sciences at Monash Health, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ³The University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁴Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁵Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁶Chang Gung University, Taoyuan County, Taiwan, ⁷Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, ⁸University of Malaya, Kuala Lumpur, Malaysia, ⁹Monash Health, Melbourne, Australia, ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹²University of Padjadjaran, Bandung, Indonesia, ¹³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁴Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶University of New South Wales, Sydney, Australia, ¹⁷Royal Adelaide Hospital, Adelaide, Australia, ¹⁸Medicine, The University of Hong Kong, Hong Kong, Hong Kong, ¹⁹Rheum/Immunology, Peking University People's Hospital, Beijing, China, ²⁰The University of Melbourne, Melbourne, Australia, Melbourne, Australia, ²¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: The Definitions of Remission in SLE (DORIS) group has proposed multiple definitions of remission, but these are infrequently attained and have not previously been…
Abstract Number: 1624 • 2017 ACR/ARHP Annual Meeting
SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K
Zahi Touma¹, Dafna D Gladman², Jiandong Su³, Nicole Anderson⁴ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) is one of the most commonly used disease activity indices in clinical practice and research but this…
Abstract Number: 2989 • 2014 ACR/ARHP Annual Meeting
Lupus Impact Tracker Is Responsive to Changes in Disease Activity in Lupus
David Giangreco¹, Hervé Devilliers², Narender Annapureddy¹, Joel A. Block³ and Meenakshi Jolly¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ³Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patient reported outcomes (PRO) are important to understand, educate, manage and follow patients with systemic lupus erythematosus (SLE). Lupus Impact Tracker (LIT) is a…
Abstract Number: 2634 • 2014 ACR/ARHP Annual Meeting
A Signal of Improvement in Lupus Disease Activity at 3 Months Predicts Further Valid Improvement at 6 Months
Zahi Touma¹, Dafna D. Gladman², Dominique Ibanez¹ and Murray B. Urowitz², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: In patients with active disease, physicians look for an early signal in response to treatment to guide their therapeutic decisions. Systemic Lupus…
Abstract Number: 1657 • 2014 ACR/ARHP Annual Meeting
Does Advanced Age Influence the Type of Renal Injury and the Prognosis of Lupus Nephritis?
Eulalia Armengol¹, Javier Narváez², Helena Borrell¹, Sergi Heredia¹, Milagros Ricse¹, Eva Benavent³, Alex Roset³, Carmen Gomez Vaquero¹, Joan Torras⁴, Francesca Mitjavila³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that usually affects young people. Several reviews have shown that age may have an effect on…
Abstract Number: 713 • 2014 ACR/ARHP Annual Meeting
Lupuspro Is Responsive to Changes in Disease Activity over Time
David Giangreco¹, Hervé Devilliers², Narender Annapureddy¹, Joel A. Block³ and Meenakshi Jolly¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ³Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patient reported outcome (PRO) tools are important to understand, educate, manage, and follow patients with systemic lupus erythematosus (SLE). Disease targeted PRO for SLE…
Abstract Number: 2508 • 2013 ACR/ARHP Annual Meeting
Clinical and Serological Discordance In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort
Murray B. Urowitz¹, Dafna D. Gladman¹, Nicole Anderson¹ and Systemic Lupus Erythematosus International Collaborating Clinics SLICC², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Anti-DNA antibodies and serum complement levels are considered important biomarkers for disease activity in SLE. Despite this many SLE patients present serologically active (positive…
Abstract Number: 632 • 2012 ACR/ARHP Annual Meeting
The Effects of Co-Existing Proliferative Histopathology On Membranous Lupus Nephritis
Jennifer L. Graybill¹, Catarina Vila-Inda¹, Chaim Putterman² and Irene Blanco¹, ¹Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Lupus nephritis (LN) affects up to 60% of SLE patients and is worse in minority communities. Traditionally membranous LN confers a better prognosis than…
Abstract Number: 2617 • 2012 ACR/ARHP Annual Meeting
Outcomes Associated with Belimumab in Black/African American Patients with Systemic Lupus Erythematous in Clinical Practice Settings in the United States
Christopher E. Collins¹, Siva Narayanan², Maria Dall'era³, Greg Dennis⁴, Alan Oglesby⁵, Mark B. McGuire⁶, Ramesh Pappu⁷, Charles T. Molta⁸ and Greg Keenan⁴, ¹Rheumatology, Washington Hospital Ctr, Washington, DC, ²Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Human Genome Sciences, Inc., Rockville, MD, ⁵GlaxoSmithKline, Research Triangle Park, NC, ⁶Medical Data Analytics, Parsippany, NJ, ⁷GlaxoSmithKline, USA, Philadelphia, PA, ⁸GlaxoSmithKline, Philadelphia, PA
Background/Purpose: Effectiveness of belimumab in black/African American (AA) patients (pts) with Systemic Lupus Erythematous (SLE) is yet to be adequately demonstrated. The objective of this…
Abstract Number: 1417 • 2012 ACR/ARHP Annual Meeting
Favorable Response to Belimumab At Three Months
Katrina M. Shum¹, Jill P. Buyon², H. Michael Belmont¹, Andrew G. Franks Jr.³, Richard Furie⁴, Diane L. Kamen⁵, Susan Manzi⁶, Michelle Petri⁷, Rosalind Ramsey-Goldman⁸, Chung-E Tseng¹, Ronald F. van Vollenhoven⁹, Daniel Wallace¹⁰ and Anca Askanase¹, ¹NYU School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Dermatology & Medicine (Rheumatology), New York University, New York, NY, ⁴North Shore-LIJ Health System, Lake Success, NY, ⁵Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ⁶Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹The Karolinska Institute, Stockholm, Sweden, ¹⁰Cedars-Sinai/UCLA, Los Angeles, CA
Background/Purpose: Belimumab (Benlysta) is a monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the use…
Abstract Number: 1418 • 2012 ACR/ARHP Annual Meeting
Directed Intuitive Assessment of Lupus (the DIAL system for real world clinics) Correlates Well with BILAG and SLEDAI
Anca D. Askanase¹, Katrina M. Shum¹, Stan Kamp², Fredonna C. Carthen², Teresa J. Aberle³ and J.T. Merrill², ¹NYU School of Medicine, New York, NY, ²Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Disease activity measures used in SLE clinical studies, including the SLEDAI (SLE Disease Activity Index) and BILAG (British Isles Lupus Assessment Group) index are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].